Immune Checkpoint Inhibition Therapies and Molecular Cancer Biology
A postdoctoral fellowship is available in the laboratory of Thomas Kirchoff, PhD, at NYU Langone Health’s Perlmutter Cancer Center. We are a dynamic lab that studies host immunity in relation to the efficacy and toxicity of immune checkpoint inhibition (ICI) therapy. We use state-of-the art “-omics” approaches in large patient populations, in various immuno-oncology clinical trial settings and beyond.
Our work is positioned in a multidisciplinary environment that combines oncology, clinical trials, cancer genetics/immunology, and molecular cancer biology. The focus of this postdoc is the “multi-omics” investigation of large patient populations with the goal of discovering novel biomarkers of ICI outcomes that could potentially lead to actionable targets for improved ICI therapies for melanoma and other cancers. Successful candidates will be self-motivated and work well in a group environment.
Postdoc responsibilities include genomic data analysis from whole-genome sequencing, RNA-sequencing, epigenome-based next generation sequencing (ATAC-seq, CHIP-seq, Methylation-seq, etc); high-throughput genotyping (SNP arrays, etc.); bioinformatics tool development; and manuscript and grant application preparation.
Candidates must have the following qualifications:
• a PhD in bioinformatics, computer science, biostatistics, genetics, or a related field
• extensive programming experience
• prior experience with large next generation sequencing (NGS) “omics” platforms
• knowledge of genomics and statistics
• good presentation skills
We prefer candidates who have experience in cancer genome analyses, data extraction from public databases, cancer biology, manuscript writing, and algorithm design. To apply, please send your CV to Dr. Kirchhoff at firstname.lastname@example.org.